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Abstract
Background: There are no core outcome domain or measurement sets for Total Joint Replacement (TJR) clinical
trials. Our objective was to achieve an International consensus by orthopaedic surgeons on the OMERACT core
domain/area set for TJR clinical trials.
Methods: We conducted surveys of two orthopaedic surgeon cohorts, which included (1) the leadership of
international orthopaedic societies and surgeons (IOS; cohort 1), and (2) the members of the American Academy
of Orthopaedic Surgeons’ Outcome Special Interest Group (AAOS-Outcome SIG), and/or the Outcome Research
Interest Group of the Orthopaedic Research Society (ORS; cohort 2). Participants rated OMERACT-endorsed
preliminary core area set for TJR clinical trials on a 1 to 9 scale, indicating 1–3 as domain of limited importance,
4–6 being important, but not critical, and 7–9 being critical.
Results: Eighteen survey participants from the IOS group and 69 participants from the AAOS-Outcome SIG/ORS
groups completed the survey questionnaire. The median (interquartile range [IQR]) scores were seven or higher for
all six proposed preliminary core areas/domains across both groups, IOS and AAOS-Outcome SIG/ORS, respectively:
pain, 8 [8, 9] and 8 [7, 9]; function, 8 [8, 8] and 8 [7, 9]; patient satisfaction, 8 [7, 9] and 8 [7, 8]; revision surgery,
7 [6, 9] and 8 [6, 8]; adverse events, 7 [5, 8] and 7 [6, 9]; and death, 7 [7, 9] and 8 [5, 9]. Respective median
scores were lower for two additional optional domains: patient participation, 6.5 [5, 7] and 6 [5, 8]; and cost,
6 [5, 7] and 6 [5, 7].
Conclusions: This study showed that two independent surveys dervied from three groups of orthopaedic
surgeons with international representation endorsed a preliminary/draft OMERACT core domain/area set for Joint
Replacement clinical trials.
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Background
Total Joint Replacement (TJR) is one of the most common
elective procedures performed in the US and worldwide.
The rate of utilization of this highly cost effective and
clinically successful procedure has, in part, been attributed
to the increasing prevalence of osteoarthritis, obesity, and
an aging population [1–3]. Despite the recognition that
the measurement of pain and function after TJR is very
important and the common practice is to assess these
outcomes in clinical practice, there is no consensus as to
which domains or outcome measures should be included
in every TJR trial. Consistency in measurement is essential
for enabling valid comparisons between TJR clinical trials
and head-to-head studies, which currently is hampered by
the heterogeneity of outcome measures [4], and the inabil-
ity to pool data for meta-analysis. A TJR outcome Work-
ing Group (WG) first met at the OMERACT-9 meeting in
2008 where this critical issue was discussed in detail [5].
Based on the strategy outlined, we have continued the
work in this area within our WG for the last 8 years.
The method of development of TJR trial core domain
set was a multi-step, data-driven process that required a
consensus by key stakeholders, including but not limited
to orthopaedic surgeons and patients; step-by-step details
are available in a previous publication [6]. Consensus for
core domains was defined as the agreement of different
stakeholders (and different groups of the same stakeholder
type, i.e., two groups of patients or two groups of
physicians) for a similar set, if not the same, core domains.
In case of a discrepancy in ratings, we would discuss with
various stakeholders to agree to a final common domain
set, i.e., consensus. We performed two surveys among 1)
orthopaedic surgeons and 2) patients, clinicians, ortho-
paedic surgeons, and methodologists [7] that identified
seven potential domains for a draft TJR trial core domain
set (including joint-specific quality of life). At the
OMERACT-2014 meeting in Budapest, a multi-stakeholder
group including orthopaedic surgeons, patients, academic
researchers and industry scientists, discussed in detail and
by consensus endorsed a preliminary core domain set for
TJR clinical trials [6]. The TJR clinical trial preliminary core
domain set included six core domains, namely, pain, func-
tion, patient satisfaction, revision surgery, adverse events
and death [6]. Other domains were considered but not
endorsed for inclusion in the core set were patient expecta-
tions, joint-specific quality of life and generic quality of
life [6]. Joint-specific quality of life was thought to be
redundant with functional ability, pain and patient satisfac-
tion and therefore not included in core domain set, details
of the discussion are provided elsewhere [6]. We previously
determined that the next step in this consensus process
was to obtain further input from more independent groups
from two important stakeholder communities, the ortho-
paedic surgeons and the patients.
The objective of the current study was to assess whether
a broader orthopaedic community will engage in further
development of the draft TJR trial core domain set,
endorse or propose modification. We performed two
separate surveys with three groups of orthopaedic surgeons
to obtain a consensus on the draft TJR trial core domain
set. We surveyed: (1) the present/past leadership of inter-
national orthopaedic societies (IOS) (survey 1); and (2) the
members of the American Academy of Orthopaedic
Surgeons’ Outcome Special Interest Group (AAOS-Out-
come SIG) and the Outcome Research Interest Group of
the Orthopaedic Research Society (ORS) at the annual
meetings (survey 2), using each groups’ email list.
Methods
Setting
We surveyed three groups of orthopaedic surgeons, key
stakeholders for this consensus, by performing two
separate surveys. These surgeons included not only clini-
cians, but also orthopaedic clinical trialists and leading
total joint registry investigators. We met orthopaedic sur-
geons face to face at the AAOS meeting and subsequently
obtained email lists for three groups of orthopaedic sur-
geons, categorized as follows for two independent surveys:
(1) the present/past IOS leadership (survey 1); and (2) the
members of the AAOS-Outcomes SIG and the Outcome
Research Interest Group of the ORS (survey 2), who
attended the respective meetings at the AAOS-2015.
Survey and analyses
We pre-tested a survey questionnaire that queried the im-
portance of six core domains/areas (pain, function, patient
satisfaction, revision surgery, adverse event and death)
and two optional areas (patient participation in life/social
activities, cost) for reporting in joint replacement clinical
trials. Ratings were on a 1–9 scale, 1–3 indicating domain
of limited importance, 4–6 being important domain, and
7–9 being critically important domain. If both groups of
orthopaedic surgeons were to rate each core domain “7–
9”, i.e., critical, it would indicate complete consensus, and
the TJR core domain set would be considered endorsed by
orthopaedic surgeons at this stage. If a majority of the six
core domains, but not all, were rated as critical by both
orthopaedic surgeon groups, it would indicate incomplete
consensus and would lead to discussion with surgeons
regarding whether we needed modification of the draft
TJR trial core domain set. In case of lack of consensus,
modification of core domain set would be done. A similar
approach was planned for the future, in case of lack of
complete consensus between surgeon and patient surveys
for the draft TJR trial core domain set, leading either to its
endorsement or modification (separate surveys of the
same core domain set in patients) (Singh JA, et al. Patient
Endorsement of the Outcome Measures in Rheumatology
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(OMERACT) Total Joint Replacement (TJR) Clinical Trial
Draft Core Domain Set, submitted).
Summary statistics are calculated for the two cohorts
of survey participants. We calculated the median (inter-
quartile range) ratings for each of the preliminary core
domain/area within each group, the orthopaedic sur-
geon/registry leadership group and the AAOS-Outcome
SIG/ORS orthopaedic surgeon groups.
Results
There were 18 survey participants from the IOS group
and 69 participants from the AAOS-Outcomes SIG/ORS
outcome groups who completed the questionnaire. Of the
survey respondents, respectively, 100 and 78% were
male, >90% in both were arthroplasty researcher/surgeons,
and 67 and 64% were 55 years and older (Table 1).
The pattern of endorsement and ratings of both core do-
mains and optional domains for measurement in arthro-
plasty RCTs were similar across the two diverse groups of
orthopaedic surgeons (Table 2). All six proposed prelimin-
ary core domains of pain, function, patient satisfaction,
revision surgery, adverse event and death achieved a
median score of 7 or 8 on a 0–9 scale in both groups, i.e.,
were rated as critically important. The median score for two
additional optional domains, patient participation and cost,
achieved a median score of 6–6.5 in both groups (Table 2).
Several important comments were provided by survey
respondents, which shed further insight into this issue
(Table 3). Additional core domains brought up for con-
sideration by 1 respondent each were: caregiver impact;
venous thromboembolism occurrence; return to work;
quality of life; and range of motion. Some participants
commented that the domains of revision (at some speci-
fied time/s after TJR) and patient participation (social vs.
work) need to be defined clearly.
Discussion
TJR clinical trials often report outcomes that are heteroge-
neous and difficult to combine and compare across trials in
a systematic review or comparative analysis [4, 5]. This het-
erogeneity is not only a major barrier to accurate com-
parison between trials but also an impediment to the
development of consensus, which is critical for the
collective analysis of the important findings that TJR
trials may bring. The various international joint re-
placement registries have recognized the importance
of harmonizing outcome collection and reporting
based on expert consensus and have initiated a col-
laborative approach to establishing a framework [8].
To date, such an effort has not been completed for a
core measurement set in TJR clinical trials.
The OMERACT TJR Working Group, an International
group with patient partnership, is pursuing this goal
through International collaboration with groups such as the
AAOS-Outcome SIG, the ORS, the International Society of
Arthroplasty Registries (ISAR), and Functional Outcomes
in Total Joint Replacement (FORCE-TJR). In the last few
meetings, the OMERACT TJR WG has made significant
progress in assembling a multi-stakeholder group and com-
pleted the literature reviews examining the frequency of
reporting of various domains (pain, function, revision etc.)
in TJR clinical trials (Richards B, et al. Outcome measures
Table 1 Participant characteristics
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aMissing values for AAOS-Outcome SIG and OMERACT cohorts: sex: 5 vs. none;
age, 4 vs. none; bBackground, people could choose more than one option
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used in arthroplasty trials: Systematic review of the 2008
and 2013 literature, submitted; Wall P, et al. Do outcomes
reported in randomised controlled trials of joint replace-
ment surgery fulfil the OMERACT 2.0 Filter? A review of
the 2008 and 2013 literature, submitted).
At OMERACT 2014 TJR WG, a preliminary core
domain set for TJR clinical trials was developed based on
systematic literature reviews, the OMERACT filter 2.0, and
two separate surveys at orthopaedic surgery meetings and
the OMERACT pre-meeting [6]. This proposed draft TJR
core domain set (pain, function, patient satisfaction, revi-
sion, adverse events, death, joint-specific quality of life) was
discussed with a multi-stakeholder group at OMERACT-
2014 TJR WG that included patients who had undergone
arthroplasty, orthopaedic surgeons (in an academic setting
or community-based practice), psychometricians, physical/
occupational therapists, other clinicians and arthroplasty
researchers, and finally endorsed with six core domains [6].
This multi-stakeholder OMERACT group helped develop
the draft TJR clinical trial core domain set including experts
in the development of clinical trial core domain sets and
following a well-described methodology based on a solid
framework of the OMERACT filer 2.0 [9–11].
In the current study, both groups of orthopaedic sur-
geons achieved consensus on the six TJR clinical trial core
domains (scores of 7 or above) and did not propose any
new core domains. These are very important findings, since
these Delphi involved two groups of orthopaedic surgeons
independent of those who had participated in the develop-
ment of the preliminary TJR clinical trial core domain set.
This is not surprising since this TJR core domain set was
developed over several years after multiple systematic re-
views and with multi-stakeholder input consisting of ortho-
paedic surgeons, patients who had undergone arthroplasty
and methodologists who have an extensive experience with
developing and validating core domain and measurement
sets. The OMERACT’s philosophy of a multi-stakeholder
involvement from the beginning of the process, and a data
driven approach, are key to successfully achieving a broad
stakeholder consensus on this draft TJR clinical trial core
domain set. This evidence indicates that preliminary TJR
core domain set initially developed with multi-stakeholder
input and endorsed at OMERACT 2014 meeting was
endorsed independently by orthopaedic surgeons.
Core domain sets are those domains that should be re-
ported in every clinical trial for the condition, regardless of
the intervention, as they are critical to the conceptualization
of the condition/disease. One must not confuse a core do-
main with the primary outcome for each clinical trial, which
is always specific to each research question. In some studies,
core domain measures will be primary outcome, since they
are the focus of the research question; in other studies, they
may be secondary study outcomes. Our work indicates that
this draft TJR core domain set is now ready for the next
phase, namely, the identification and validation of measures
that accurately reflect each core domain, and further dis-
semination of this TJR core domain set to key stakeholders.
We received qualitative feedback from the surveys,
which has helped us with further specification of two
core domains. One suggestion was to consider any reop-
eration, not just revision, due to its relevance to pa-
tients- this indicates that the core domain would be
revision/reoperation. Another suggestion was to specify
whether death was procedure-related vs. not procedure-
related. With further refinement of the core domains,
these two proposals will be the subject of future WG
discussions. It is interesting and reassuring that several
of domains brought up one participant each (caregiver
impact; venous thromboembolism occurrence; return to
work; quality of life; and range of motion) were consid-
ered previously. Based on Delphi and detailed discus-
sions with surgeons, patients and other stakeholders,
Table 2 Preliminary core areas/domains for TJR clinical trials





Main Domains to be reported in every TJR clinical trial
Joint Pain 8 [8, 9] 8 [7, 9]
Function or functional ability (ability to function in society, work;
work productivity, employability; disability; work disability)
8 [8, 8] 8 [7, 9]
Patient Satisfaction (satisfaction with the outcome, satisfaction
with the procedure)
8 [7, 9] 8 [7, 8]
Revision surgery 7 [6, 9] 8 [6, 8]
Adverse events 7 [5, 8] 7 [6, 9]
Death 7 [7, 9] 8 [5, 9]
Additional domains for consideration for reporting in TJR clinical trials
Patient Participation 6.5 [5, 7] 6 [5, 8]
Cost 6 [5, 7] 6 [5, 7]
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they were recommended not for inclusion in the core
domain set, since they were not considered to represent
an independent core domain, above and beyond the six
domains already included.
We noted that both groups independently rated the
additional non-core domains (patient participation, cost)
as important but not critical; the median scores were 6
to 6.5, appropriately lower than the core domains, since
these are not core domains. Non-core domains are those
domains that may be additionally reported in a TJR clin-
ical trial, depending on the clinical question being asked.
Our study findings must be interpreted with caution,
since they may not be generalizable to other groups.
Our orthopaedic surgeon samples were 78 and 100%
male, which may limit the generalizability of the findings
to all surgeons. The gender distribution among ortho-
paedic surgeons is not balanced in general. We devel-
oped this draft TJR core domain set for clinical trials; it
is possible that with validation and future work, this set
or a similar set may be endorsed for observational stud-
ies as well.
Our study has several strengths, including use of the
same survey in two groups of stakeholders, inclusion of
both leaders of orthopaedic societies as well as the group
of orthopaedic surgeons and researchers from commu-
nity and academic practices.
Conclusions
In conclusion, the current study shows further inde-
pendent endorsement of the draft TJR core domain set
for reporting of TJR clinical trials. The next steps in this
process, are a wider endorsement of these by OMER-
ACT and/or orthopaedic organizations that we have
been collaborating with. This will be followed by the
development of a valid, data- and consensus-driven TJR
clinical trial core outcome measurement set. Our group
will aim to complete this step over the next 2 years. The
process will be completed with multi-stakeholder input
with a particular emphasis of involvement of patients
and TJR surgeons.
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